ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Roche Holding Ag

Roche Holding Ag (0QQ6)

229.20
0.00
(0.00%)
終了 1月6日 1:30AM

個人投資家向けのプロ仕様のツール。

主要統計と詳細

通貨
229.20
買値
0.00
売値
0.00
出来高
651
0.00 日の範囲 0.00
229.20 52 週間の範囲 229.20
時価総額
前日終値
229.20
始値
-
最終取引時間
財務取引量
-
VWAP
-
平均取引量 (3 か月)
4,792
発行済株式数
0.00
配当利回り
-
PER
0.00
1 株当たり利益 (EPS)
-
歳入
58.72B
純利益
11.5B

Roche Holding Ag について

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Basel, Che
設立
-
Roche Holding Ag is listed in the Pharmaceutical Preparations sector of the ロンドン証券取引所 with ticker 0QQ6. The last closing price for Roche was CHF229.20. Over the last year, Roche shares have traded in a share price range of CHF 229.20 to CHF 229.20.

Roche currently has 0 shares in issue.

0QQ6 最新ニュース

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease PADOVA study showed numerical delay in motor progression and...

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical labClinical...

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness Vabysmo PFS is the first and only prefilled syringe containing a bispecific...

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities The new cobas 6800/8800 systems 2.0 enhances throughput, run...

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma Long-term data confirm fixed-duration...

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash Basel, 9...

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma Exploratory long-term follow-up analysis of the phase III POLARIX...

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma Application is based on data from the...

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies Acquisition supports Roche’s Pharma Strategy and...

Roche reports update on Phase III SKYSCRAPER-01 study results

Roche reports update on Phase III SKYSCRAPER-01 study results Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
100229.2229.2229.2937229.2DE
400229.2229.2229.25535229.2DE
1200229.2229.2229.24792229.2DE
2600229.2229.2229.24445229.2DE
5200229.2229.2229.25209229.2DE
15600229.2229.2229.26094229.2DE
26000229.2229.2229.24941229.2DE

0QQ6 - Frequently Asked Questions (FAQ)

What is the current Roche share price?
The current share price of Roche is CHF 229.20
What is the 1 year trading range for Roche share price?
Roche has traded in the range of CHF 229.20 to CHF 229.20 during the past year
What is the reporting currency for Roche?
Roche reports financial results in CHF
What is the latest annual turnover for Roche?
The latest annual turnover of Roche is CHF 58.72B
What is the latest annual profit for Roche?
The latest annual profit of Roche is CHF 11.5B
What is the registered address of Roche?
The registered address for Roche is GRENZACHERSTRASSE 124, BASEL, 4070
What is the Roche website address?
The website address for Roche is www.roche.com
Which industry sector does Roche operate in?
Roche operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

最近閲覧した銘柄

Delayed Upgrade Clock